Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 28

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 28
---
 expect to fund the patent costs from our cash and restricted cash. The value of our drug products will depend significantly on our ability to obtain and maintain patent and other proprietary protection for those products, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of other parties. As of the date hereof, we are the patentee of a number of provisional and non-provisional patent applications, both on our proprietarily developed projects and improvement to our in-licensed projects. The following table sets forth a list of our patent rights as of the date hereof related to our Lead Projects; SACT-1 is a proprietary technology not subject to any license agreement:

| Project         
 Company/Project 
 name            |     | Ownership Type                                                 |     | Licensor(s)       |     | Licensee                       |     | Licensed/IP Rights                                                                                            |     | Patent Expiration                                                               
 Dates                                                                           |
| Acticule/ALS-4  |     | Exclusive Patent License Agreement, dated October 18, 2017     
 First Amendment to Exclusive License Agreement, dated June 7,  
 2018                                                           
 Second Amendment to Exclusive License Agreement dated July 10, 
 2019                                                           
 Exclusive Patent License Agreement dated January 11, 2019      |     | Versitech Limited |     | Acticule Life Sciences Limited |     | Exclusive licensee: 2 pending U.S. applications (16/867,540 and 17/006,985), 2 pending applications in Canada |     | The licensed IP rights include granted patents in the U.S. and                  
 pending patent applications in the U.S., and Canada.                            
 The U.S. patents will expire in 2038; any other patent based on                 
 the pending application, if granted, will have a 20-year patent term from 2018. |
| SACT-1          |     | Self-owned Patent                                              |     | N/A               |     | N/A                            |     | U.S. Patent No. 11,166,952 & U.S. Patent No. 11,571,422                                                       |     | Both patents expire on November 27, 2040.                                       |

Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.